Silvana Konermann

Yeah, I mean, that's definitely a question that I think, as you know, we got during the audacious process.

I think the key thing to keep in mind that this is really just for human cells.

We could, in theory, someone could build this kind of tool for a virus.

And I would say, don't do that.

That's a bad idea.

Because yes, then you can absolutely use it to create something that will be dangerous.

But this really just allows you to shift human cells into a different state.

And I think that would be pretty difficult to abuse.

And in principle, if a nasty virus did come along and this model is working properly, that's a way of giving us one of the quickest... Yeah, I mean, it will tell you, for example, how you know the virus is targeting this gene in the cell.

Right now, we know, OK, we know what happens to the cell when that's getting targeted.

So, yeah, it will absolutely help us to defend.

Yeah.

Yeah, so ARC really was only started in 2021.

It's kind of when we decided to launch.

2022 is really when we got up and running.

So it's only been four years, but we've grown a lot.

We're over 300 people now, and I think one thing we really wanted to be able to achieve with ARC is to bring people together from different disciplines and have AI and biology under one roof in one institute.

And we started just around the right time, where we could see what machine learning was going to mean for biology.

Yeah, I mean, I would say that I really think biomedicine is going to transform for these kinds of diseases, right?

Not maybe in three months, right?